[Therapy of fungal septicemia and bounds (author's transl)].
The authors present the results of therapy in 26 cases of fungal septicemia occurring in a 2,471 patients population with 169 septicemia, over a 9 year period in a surgical intensive care service. An analysis of the etiology, clinical and paraclinical factors confirms the notions classically described in the literature. Three points are particularly insisted upon: 1) The effectiveness of preventive measures; 2) The monitoring of the therapy and its tolerance by means of a simple protocol; 3) The eventual possibility of an haematologic toxicity by flucytosine, the primary and secondary resistances to this anti-fungal agent. The strict application of preventive measures seems to reduce the incidence of fungal septicemia but not to eradicate them. The prognosis of these states remains grave.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use*; D002176:Candida albicans; D002177:Candidiasis / Q000188:drug therapy; D003596:Cytosine / Q000031:analogs & derivatives*; D004361:Drug Tolerance; D005260:Female; D005437:Flucytosine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy*; D011183:Postoperative Complications / Q000517:prevention & control; D018805:Sepsis / Q000188:drug therapy* / Q000209:etiology; D014946:Wound Infection / Q000517:prevention & control
D000666:Amphotericin B; D003596:Cytosine; D005437:Flucytosine
Le traitement des septicémies à levures. Ses limites.